Is there a benefit of131I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of the German Neuroblastoma Trial NB97 and implications for the The German Neuroblastoma Trial NB2004

NuklearMedizin

Volumn 45, Issue 4, 2006, Pages 145-151

  Schmidt, Matthias ^a   Simon, T ^a   Hero, B ^a   Eschner, W ^a   Dietlein, M ^a   Sudbrock, F ^a   Bongartz, R ^a   Berthold, F ^a   Schicha, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

131I MIBG therapy; High risk neuroblastoma; Stage 4 neuroblastoma

Indexed keywords

131 META IODOBENZYLGUANIDINE; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER STAGING; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; UNIVARIATE ANALYSIS;

EID: 33748565275     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625111     Document Type: Article

References (31)

1. Berthold F, Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 2000; 59: 1261-77.
2. Berthold F, Hero B, Kremens B et al. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett 2003; 197: 11-7.
3. Berthold F, Boos J, Burdach S et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005; 6: 649-58.
4. Biermann M, Pixberg MK, Schuck A et al. Multicenter trial differentiated thyroid carcinoma (MSDS): diminished acceptance of adjuvant external beam radiotherapy. Nuklearmedizin 2003; 42: 244-50.
5. Brodeur GM, Prichard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-77.
6. Collett D. Strategy for model selection. In: Modelling survival data in medical research. London, Chapman and Hall 1994; 78-83.
7. DuBois SG, Messina J, Maris JM et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004; 22: 2452-60.
8. Franzius C, Lang K, Wormaans D et al. PET/CT und PET - Einsatz in der pädiatrischen Onkologie. Der Nuklearmediziner 2004; 27: 315-23.
9. 11C-HED. Nuklearmedizin 2005; 44: N4-5.
10. 131I-metaiodobenzylguanidine. Cancer 1991; 67: 922-8.
11. 131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br J Cancer 1999; 81: 1378-84.
12. 131I- metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma. J Nucl Biol Med 1991; 35: 202-6.
13. Hoefhagel CA, Lewington VJ. MIBG therapy In: Ell PJ, Gambhir SS (eds). Nuclear medicine in clinical diagnosis and treatment. Edinburgh, London, New York: Churchill Livingstone 2004; 445-57.
14. Kaatsch P, Spix C. Annual report 2003. Mainz, German Childhood Cancer Registry 2004; 72.
15. Kang TI, Brophy P, Hickeson M et al. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol 2003; 25: 769-73.
16. 131I-meta-iodobenzylguanidine, high-dose chemotherapy and immunotherapy. A pilot trial. Eur J Cancer 1998; 34: 1398-402.
17. Klingebiel T, Berthold F, Treuner J. Metabenzylguanidin (MIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial. Med Ped Oncol 1991; 19: 84-8.
18. 131I- metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects. Cancer Chemother Pharmacol 1989; 25: 143-8.
19. 123I-iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med 2000; 27: 302-7.
20. 123I-iodobenzylguanidine in clinical studies. Eur J Nucl Med 2001; 28: 1437.
21. Lashford LS, Lewis IJ, Fielding SL et al. Phase I/II trial of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Trial Group investigation. J Clin Oncol 1992; 10: 1889-96.
22. Matthay KK. Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma. Pediatr Transplant 1999; 3 (Suppl 1): 72-7.
23. 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16: 229-36.
24. 131I metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant 2001; 27: 571-4.
25. Özer S, Dobrozemsky G, Kienast O et al. Value of combined XCT/SPECT technology for avoiding false positive planar 123I-MIBG scintigraphy. Nuklearmedizin 2004; 43: 164-70.
26. Oliver P, Colarinha P, Fettich J et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003; 30: BP45-50.
27. Sisson JC, Frager MS, Valk TW et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981; 305: 12-7.
28. 125I MIBG. Am J Clin Oncol 1996; 19: 144-8.
29. Staak JO, Dietlein M, Engert A et al. Hodgkin's lymphoma in nuclear medicine: diagnostic and therapeutic aspects. Nuklearmedizin 2003; 42: 19-24.
30. Troncone L, Rufini V, Montemaggi P et al. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years experience. Eur J Nucl Med 1990; 16: 325-35.
31. Yanik GA, Levine JE, Matthay KK et al. Pilot trial of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002; 20: 2142-9.